Memorial Sloan Kettering Cancer Center Update in Hematology and Medical Oncology 2026

200 $

+ Include: 47 videos + 47 file sub vtt + 49 pdfs, size: 15.81 GB

+ Target Audience: hematologists and medical oncologists

Description

+ Include: 47 videos + 47 file sub vtt + 49 pdfs, size: 15.81 GB

+ Target Audience: hematologists and medical oncologists

+ Sample video: contact me for sample video

+ Information:

1. Overview

The Memorial Sloan Kettering Cancer Center 2026 Update in Hematology and Medical Oncology and 14th Annual Board Review is a four-day comprehensive course offering an in-depth, current review of the diagnosis, staging, and management of neoplastic diseases across both solid tumors and hematologic malignancies. Expert-led lectures cover a wide spectrum of disease-specific topics, including gastrointestinal, gynecologic, thoracic, head and neck, genitourinary, soft tissue and skin, and central nervous system oncology, in addition to hematologic oncology.

Course Date: Friday, March 13, 2026, 9:10 AM – Monday, March 16, 2026, 4:00 PM, Online

This course is designed for medical oncology professionals — including physicians, nurses, pharmacists, advanced practice providers, fellows, and residents — seeking a comprehensive update in Medical Oncology and Hematology.

2. Learning Objectives

  1. Define state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers and hematologic cancers
  2. Discuss recent treatment advances in solid tumor and hematologic oncology and apply knowledge gained in modern clinical practice
  3. Prepare for ABIM examinations in medical oncology and hematology

3. Target Audience

Best for hematologists and medical oncologists who want comprehensive updates on the management of hematologic malignancies and solid tumors.

4. Topics

  1. Acute Lymphocytic Leukemia

  2. Acute Myeloid Leukemia

  3. Anal and Rectal Cancers

  4. Anticoagulation- Update on an Evolving Field

  5. Apporach to the Bleeding Patient

  6. Auto _Allo

  7. Breast Cancer- Radiation Therapy

  8. Breast Cancer- Surgery

  9. CAR T Cell

  10. Carcinoma of Unknown Primary

  11. Central Nervous System Tumors

  12. Chronic Lymphocytic Leukemia _Small Lymphocytic Lymphoma

  13. Chronic Myelogenous Leukemia

  14. Clinical Indications for Use of Blood Products and Associated Risks

  15. Colon Cancer

  16. Diffuse Large B-Cell Lymphoma _Mantle Cell Lymphoma _Burkitt Lymphoma

  17. Esophageal and Gastric Cancers

  18. Head and Neck, Thyroid, and Non-Melanoma Skin Cancers

  19. Hemolytic Anemia

  20. Hepatocellular Cancer and Cholangiocarcinoma

  21. HER2-Positive Breast Cancer

  22. Hereditary Cancer Genetics

  23. Hodgkin Lymphoma_T Cell

  24. Hormone Receptor-Positive Breast Cancer

  25. Infectious Disease

  26. Kidney Cancer

  27. Low-Grade Non-Hodgkin Lymphoma

  28. Melanoma

  29. Mesothelioma

  30. Myelodysplastic

  31. Myeloma_Amyloid

  32. Myeloproliferative Neoplasms

  33. Non-Small Cell Lung Cancer

  34. Ovarian Cancer

  35. Pancreatic and Neuroendocrine Cancers

  36. Pharmacology I_II

  37. Prostate Cancer

  38. Sarcoma

  39. Sickle Cell Disease, Thalassemia

  40. Small Cell Lung Cancer

  41. Testis Cancer

  42. Thrombocytopenia and ITP

  43. Thrombotic Disorders

  44. Transfusion Reactions

  45. Triple-Negative Breast Cancer

  46. Urothelial Cancer

  47. Uterine, Cervix, and Other Gynecologic Cancers

  48. 2026 Post-Test HemOnc Board Review

Reviews

There are no reviews yet.

Be the first to review “Memorial Sloan Kettering Cancer Center Update in Hematology and Medical Oncology 2026”

Your email address will not be published. Required fields are marked *

35 − 27 =
Powered by MathCaptcha